Skip to main content
Pankaj Bhargava, MD, Oncology, Boston, MA

PankajBhargavaMD

Oncology Boston, MA

Physician

Are you Dr. Bhargava?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 51 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    44 Binney St
    Danafarber Cancer Institute
    Boston, MA 02115
    Phone+1 617-632-6184
    Fax+1 617-632-5370

Summary

  • Dr. Pankaj Bhargava, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, California, and District of Columbia. He is affiliated with Dana-Farber Cancer Institute and Salem Hospital.

Education & Training

  • Georgetown University Hospital
    Georgetown University HospitalFellowship, Medical Oncology, 1995 - 1997
  • Maimonides Medical Center
    Maimonides Medical CenterResidency, Internal Medicine, 1992 - 1995
  • Delhi University College of Medical Sciences
    Delhi University College of Medical SciencesClass of 1991

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 1996 - Present
  • CA State Medical License
    CA State Medical License 2007 - 2024
  • MA State Medical License
    MA State Medical License 2000 - 2020
  • VA State Medical License
    VA State Medical License 1996 - 2018
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive Partner
    MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive PartnerApril 13th, 2021
  • Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
    Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)May 13th, 2016
  • Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical Officer
    Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical OfficerApril 2nd, 2014

Professional Memberships